Production, Passaging Stability, and Histological Analysis of Madin-Darby Canine Kidney Cells Cultured in a Low-Serum Medium.

MDCK cells RNA sequencing flu vaccine low-serum medium proteomics

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 04 07 2024
revised: 02 08 2024
accepted: 28 08 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

Madin-Darby canine kidney (MDCK) cells are commonly used to produce cell-based influenza vaccines. However, the role of the low-serum medium on the proliferation of MDCK cells and the propagation of the influenza virus has not been well studied. In the present study, we used 5 of 15 culture methods with different concentrations of a mixed medium and neonatal bovine serum (NBS) to determine the best culture medium. We found that a VP:M199 ratio of 1:2 (3% NBS) was suitable for culturing MDCK cells. Furthermore, the stable growth of MDCK cells and the production of the influenza virus were evaluated over long-term passaging. We found no significant difference in terms of cell growth and virus production between high and low passages of MDCK cells under low-serum culture conditions, regardless of influenza virus infection. Lastly, we performed a comparison of the transcriptomics and proteomics of MDCK cells cultured in VP:M199 = 1:2 (3% NBS) with those cultured in VP:M199 = 1:2 (5% NBS) before and after influenza virus infection. The transcriptome analysis showed that differentially expressed genes were predominantly enriched in the metabolic pathway and MAPK signaling pathway, indicating an activated state. This suggests that decreasing the concentration of serum in the medium from 5% to 3% may increase the metabolic activity of cells. Proteomics analysis showed that only a small number of differentially expressed proteins could not be enriched for analysis, indicating minimal difference in the protein levels of MDCK cells when the serum concentration in the medium was decreased from 5% to 3%. Altogether, our findings suggest that the screening and application of a low-serum medium provide a background for the development and optimization of cell-based influenza vaccines.

Identifiants

pubmed: 39340023
pii: vaccines12090991
doi: 10.3390/vaccines12090991
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Wuhan Science and Technology Bureau
ID : 2022023702025187

Auteurs

Ming Cai (M)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Yang Le (Y)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Zheng Gong (Z)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Tianbao Dong (T)

Center for Drug Evaluation and Inspection of HMPA (Hubei Center for Vaccine Inspection), Wuhan 430207, China.

Bo Liu (B)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Minne Su (M)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Xuedan Li (X)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Feixia Peng (F)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Qingda Li (Q)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Xuanxuan Nian (X)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Hao Yu (H)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Zheng Wu (Z)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Zhegang Zhang (Z)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Jiayou Zhang (J)

Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan 430207, China.
Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.

Classifications MeSH